Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy / Carsten Schmidt, Thomas Giese, Eva Hermann, Stefan Zeuzem, Stefan C. Meuer, and Andreas Stallmach
BACKGROUND: Concentrations of proinflammatory cytokines are increased in the intestinal mucosa of patients with active Crohn's disease (CD). In a prospective study we investigated whether cytokines can predict long-term remission (>6 months) in patients with steroid-refractory CD receiving treatment with infliximab or cyclophosphamide, followed by azathioprine or methotrexate. METHODS: Cytokine transcripts were quantified using real-time polymerase chain reaction (PCR) in mucosal biopsies from 19 patients with active, steroid-refractory CD before and 8 weeks after initiation of therapy. Patients were treated with cyclophosphamide (monthly treatment of 750 mg cyclophosphamide intravenously) or infliximab (5 mg/kg body weight) and were followed until relapse of the disease. Statistical analysis was performed to identify predictive factors to discriminate between patients with or without long-term remission. RESULTS: Seventeen out of 19 patients achieved remission of the disease, two patients were nonresponders, while six out of 17 patients exhibited an early recurrence. Pretreatment TNF-alpha, IL-18, MRP-14, and IL-8 transcripts were significantly correlated with long-term remission. While several cytokines, most importantly MMP-1, determined after 8 weeks were able to predict patients achieving long-term remission, only a decrease of TNF-alpha levels after 8 weeks was predictive. Overall, statistical analysis identified lower pretreatment TNF-alpha levels as the strongest predictor of long-term remission among baseline variables. CONCLUSIONS: Quantification of mucosal TNF-alpha transcripts prior to therapy allows identification of patients achieving long-term remission upon immunosuppression with infliximab or cyclophosphamide. Real-time PCR might have considerable potential in the analysis of disease activity and subsequent clinical management of patients with immunosuppressive therapies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2007 |
|---|---|
| Erschienen: |
2007 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Inflammatory bowel diseases - 13(2007), 1, Seite 65-70 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schmidt, Carsten, 1968- [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
Gesehen am 16.06.2021 |
|---|
| Umfang: |
6 |
|---|
| doi: |
10.1002/ibd.20012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1760544183 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1760544183 | ||
| 003 | DE-627 | ||
| 005 | 20230428014429.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210616s2007 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ibd.20012 |2 doi | |
| 035 | |a (DE-627)1760544183 | ||
| 035 | |a (DE-599)KXP1760544183 | ||
| 035 | |a (OCoLC)1341416349 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schmidt, Carsten |d 1968- |e verfasserin |0 (DE-588)122932749 |0 (DE-627)082242798 |0 (DE-576)302554599 |4 aut | |
| 245 | 1 | 0 | |a Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy |c Carsten Schmidt, Thomas Giese, Eva Hermann, Stefan Zeuzem, Stefan C. Meuer, and Andreas Stallmach |
| 264 | 1 | |c 2007 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.06.2021 | ||
| 520 | |a BACKGROUND: Concentrations of proinflammatory cytokines are increased in the intestinal mucosa of patients with active Crohn's disease (CD). In a prospective study we investigated whether cytokines can predict long-term remission (>6 months) in patients with steroid-refractory CD receiving treatment with infliximab or cyclophosphamide, followed by azathioprine or methotrexate. METHODS: Cytokine transcripts were quantified using real-time polymerase chain reaction (PCR) in mucosal biopsies from 19 patients with active, steroid-refractory CD before and 8 weeks after initiation of therapy. Patients were treated with cyclophosphamide (monthly treatment of 750 mg cyclophosphamide intravenously) or infliximab (5 mg/kg body weight) and were followed until relapse of the disease. Statistical analysis was performed to identify predictive factors to discriminate between patients with or without long-term remission. RESULTS: Seventeen out of 19 patients achieved remission of the disease, two patients were nonresponders, while six out of 17 patients exhibited an early recurrence. Pretreatment TNF-alpha, IL-18, MRP-14, and IL-8 transcripts were significantly correlated with long-term remission. While several cytokines, most importantly MMP-1, determined after 8 weeks were able to predict patients achieving long-term remission, only a decrease of TNF-alpha levels after 8 weeks was predictive. Overall, statistical analysis identified lower pretreatment TNF-alpha levels as the strongest predictor of long-term remission among baseline variables. CONCLUSIONS: Quantification of mucosal TNF-alpha transcripts prior to therapy allows identification of patients achieving long-term remission upon immunosuppression with infliximab or cyclophosphamide. Real-time PCR might have considerable potential in the analysis of disease activity and subsequent clinical management of patients with immunosuppressive therapies. | ||
| 650 | 4 | |a Adolescent | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Antibodies, Monoclonal | |
| 650 | 4 | |a Chemokines | |
| 650 | 4 | |a Crohn Disease | |
| 650 | 4 | |a Cyclophosphamide | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Drug Resistance | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Gastrointestinal Agents | |
| 650 | 4 | |a Glucocorticoids | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Immunosuppressive Agents | |
| 650 | 4 | |a Infliximab | |
| 650 | 4 | |a Intestinal Mucosa | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Prednisolone | |
| 650 | 4 | |a Remission Induction | |
| 650 | 4 | |a Tumor Necrosis Factor-alpha | |
| 700 | 1 | |a Giese, Thomas |d 1962- |e verfasserin |0 (DE-588)143133543 |0 (DE-627)704399075 |0 (DE-576)333724496 |4 aut | |
| 700 | 1 | |a Hermann, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Zeuzem, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Meuer, Stefan |d 1951- |e verfasserin |0 (DE-588)1020440198 |0 (DE-627)691221286 |0 (DE-576)360422454 |4 aut | |
| 700 | 1 | |a Stallmach, Andreas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammatory bowel diseases |d Oxford : Oxford University Press, 1995 |g 13(2007), 1, Seite 65-70 |h Online-Ressource |w (DE-627)340075406 |w (DE-600)2065065-6 |w (DE-576)098546589 |x 1536-4844 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2007 |g number:1 |g pages:65-70 |g extent:6 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1002/ibd.20012 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4338 | ||
| 936 | u | w | |d 13 |j 2007 |e 1 |h 65-70 |g 6 |
| 951 | |a AR | ||
| 952 | |d 13 |j 2007 |e 1 |h 65-70 |g 6 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 3938701609 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 16-06-21 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2007 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_6 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_6 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1436258081 |a Giese, Thomas | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416741488 |a Institut für Immunologie und Serologie | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_2 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1430432594 |a Meuer, Stefan | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416741488 |a Institut für Immunologie und Serologie | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_5 | ||